Vistagen unveils new January 2026 corporate deck

Vistagen Therapeutics, Inc. filed a current report to let investors know it has begun using a new corporate presentation as of January 9, 2026.

Rhea-AI Filing Summary

Vistagen Therapeutics, Inc. filed a current report to let investors know it has begun using a new corporate presentation as of January 9, 2026. The presentation is attached as Exhibit 99.1 and is described as the company’s corporate presentation dated January 2026.

The company notes that the information in this presentation is being furnished, not filed, which means it is not subject to certain liability provisions of the Securities Exchange Act and is not automatically incorporated into other SEC filings unless specifically referenced. No financial results, major transactions, or other operational changes are described in this report; the focus is on making the updated investor presentation publicly available.

8-K Event Classification

2 items: 7.01, 9.01

2 items

Item 7.01 Regulation FD Disclosure Disclosure

Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

FAQ

What did Vistagen Therapeutics (VTGN) report in this 8-K?

Vistagen Therapeutics reported that it began using a new corporate presentation on January 9, 2026, which is attached as Exhibit 99.1.

What is included in Exhibit 99.1 for Vistagen Therapeutics (VTGN)?

Exhibit 99.1 contains the Vistagen Therapeutics, Inc. Corporate Presentation dated January 2026.

Is the new Vistagen (VTGN) presentation considered filed with the SEC?

The company states that the information under Item 7.01 and Exhibit 99.1 is furnished and not deemed filed for purposes of Section 18 of the Exchange Act.

Does this Vistagen (VTGN) 8-K disclose new financial results?

No specific financial results or earnings data are described in this report; it focuses on the availability of the new corporate presentation.

Which exchange is Vistagen Therapeutics (VTGN) listed on?

Vistagen Therapeutics’ common stock trades on the Nasdaq Capital Market under the symbol VTGN.

Who signed this Vistagen Therapeutics (VTGN) 8-K?

The report was signed on behalf of Vistagen Therapeutics, Inc. by Shawn K. Singh, its President and Chief Executive Officer, dated January 9, 2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 01/09/2026 - 05:26 PM Learn about SEC filing dates

FALSE000141168500014116852024-09-232024-09-23

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) of the SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): January 9, 2026

Vistagen Therapeutics, Inc.

(Exact name of registrant as specified in its charter)

Nevada			000-54014			20-5093315
(State or other jurisdiction of incorporation)			(Commission File Number)			(IRS Employer Identification Number)

343 Allerton Ave.

South San Francisco, California 94080

(Address of principal executive offices)

(650) 577-3600

(Registrant’s telephone number, including area code)

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a -12)

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d -2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e -4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class			Trading Symbol(s)			Name of each exchange on which registered
Common Stock, par value $0.001 per share			VTGN			Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR 230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR 240.12b-2)

Emerging Growth Company o

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act o

Item 7.01 Regulation FD Disclosure.

On January 9, 2026, Vistagen Therapeutics, Inc. (the “Company”) began utilizing a new corporate presentation, a copy of which is attached to this Current Report on Form 8-K as Exhibit 99.1.

The information under this Item 7.01 and Exhibit 99.1 attached hereto are intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Item 9.01 Financial Statements and Exhibits.

(d)Exhibits Index

Exhibit No.						Description
99.1						Vistagen Therapeutics, Inc. Corporate Presentation, dated January 2026
104						Cover Page Interactive Data File (embedded within the Inline XBRL document)

Signatures

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

			Vistagen Therapeutics, Inc.
Date: January 9, 2026			By:			/s/ Shawn K. Singh
						Shawn K. Singh President and Chief Executive Officer